CoronaryAtlas logo
CoronaryAtlas
Phosphatidic acid
Pathway / Myocardial injury (shared endpoint)

Phosphatidic acid

lipid

Phospholipid dysregulated in myocardial ischemia-reperfusion injury and cardiomyocyte damage.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleLipid dysregulation in myocardial ischemia-reperfusion injury and cardiomyocyte death.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
58
C — confounder / Type-II
65
A — assay feasibility
40
E — evidence strength
26
T1DI (composite)
5
Specificity differential (R−C)-7.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(2)